MARX Biotech Co., Ltd. (TPEX:7731)
3.640
-0.310 (-7.85%)
Nov 20, 2026, 1:49 PM CST
MARX Biotech Revenue
MARX Biotech had revenue of 257.81M TWD in the half year ending June 30, 2026, with 20.32% growth. This brings the company's total for the last twelve months to 584.74M, down -17.97% year-over-year. In the year 2025, MARX Biotech had annual revenue of 635.85M with 2.85% growth. That makes MARX Biotech the 34,598th largest company in the world by revenue and 1,802nd in Taiwan.
Revenue (ttm)
584.74M
Revenue Growth
-17.97%
P/S Ratio
3.25
Revenue / Employee
n/a
Employees
80
Market Cap
1.90B
Revenue by Geography
- Taiwan 632.33M 99.4%
- United State 1.75M 0.3%
- China 967.00K 0.2%
- Singapore and Malaysia 800.00K 0.1%
Fiscal year ended Dec 31, 2025 See the full MARX Biotech breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 635.85M | 17.63M | 2.85% |
| Dec 31, 2024 | 618.23M | 328.30M | 113.24% |
| Dec 31, 2023 | 289.93M | 179.28M | 162.04% |
| Dec 31, 2022 | 110.64M | - | - |
| Dec 31, 2021 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| PharmaEssentia | 24.62B |
| MedFirst Healthcare Services | 8.09B |
| OK Biotech | 1.72B |
| Dynamic Medical Technologies | 1.42B |
| BIONET | 1.32B |
| HeXun Biosciences | 305.13M |
| GlycoNex Incorporation | 19.51M |
| Caliway Biopharmaceuticals | 15.98M |